2-(2-Methylpyridin-4-yl)guanidine | 1584149-27-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(2-Methylpyridin-4-yl)guanidine
• CAS: 1584149-27-8
• 化学式: C₇H₁₀N₄
• 分子量: 150.183
• InChiKey: YJNWVUFVINZNPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  77.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-((dimethylamino)methylene)-3-oxopiperidine-1-carboxylate 、 2-(2-Methylpyridin-4-yl)guanidine 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 18.0h， 生成 tert-butyl 2-(2-methylpyridin-4-ylamino)-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate
  参考文献：
  名称：

  Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2

  摘要：

  The discovery and optimization of a series of tetrahydropyridopyrimidine based extracellular signal-regulated kinase (Erks) inhibitors discovered via HTS and structure based drug design is reported. The compounds demonstrate potent and selective inhibition of Erk2 and knockdown of phospho-RSK levels in HepG2 cells and tumor xenografts. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.04.068
• 作为产物：
  描述：

  在 10 wt% Pd(OH)2 on carbon 、 氢气 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 16.0h， 生成 2-(2-Methylpyridin-4-yl)guanidine
  参考文献：
  名称：

  Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2

  摘要：

  The discovery and optimization of a series of tetrahydropyridopyrimidine based extracellular signal-regulated kinase (Erks) inhibitors discovered via HTS and structure based drug design is reported. The compounds demonstrate potent and selective inhibition of Erk2 and knockdown of phospho-RSK levels in HepG2 cells and tumor xenografts. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.04.068

文献信息

• [EN] DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS<br/>[FR] DIHYDROPYRROLIDINOPYRIMIDINES COMME INHIBITEURS DE KINASE
  申请人：NOVARTIS AG

  公开号：WO2014047020A1

  公开（公告）日：2014-03-27

  The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof; as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions. These are useful in the treatment of diseases such as cancer that are associated with activation of ERKl and/or ERK2, and especially for MAPK pathway dependent cancers showing resistance to Raf and/or MEK inhibitory cancer therapeutics

  本发明提供了式(I)的化合物及其药用盐；如本文所述。本发明进一步提供了包含这些化合物的药物组合物，以及与治疗协同剂结合或使用的这些化合物的组合物，以及这些化合物和组合物的治疗用途。这些在治疗与ERKl和/或ERK2激活相关的癌症等疾病方面非常有用，特别适用于对Raf和/或MEK抑制癌症治疗药物显示抵抗的MAPK信号通路依赖性癌症。
• DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS
  申请人：DILLON Michael Patrick

  公开号：US20150274733A1

  公开（公告）日：2015-10-01

  The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof; as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions. These are useful in the treatment of diseases such as cancer that are associated with activation of ERK1 and/or ERK2, and especially for MAPK pathway dependent cancers showing resistance to Raf and/or MEK inhibitory cancer therapeutics

  本发明提供了式（I）的化合物及其药学上可接受的盐；如本文所述。本发明还提供了包含这些化合物的制药组合物，并与治疗协同剂联合使用或与治疗协同剂一起使用的组合物，以及这些化合物和组合物的治疗用途。这些化合物和组合物在治疗与ERK1和/或ERK2激活相关的疾病，特别是对于显示对Raf和/或MEK抑制性癌症治疗药物耐药的MAPK通路依赖性癌症的治疗非常有用。
• US9546173B2
  申请人：——

  公开号：US9546173B2

  公开（公告）日：2017-01-17
• Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2
  作者：James F. Blake、John J. Gaudino、Jason De Meese、Peter Mohr、Mark Chicarelli、Hongqi Tian、Rustam Garrey、Allen Thomas、Christopher S. Siedem、Michael B. Welch、Gabrielle Kolakowski、Robert Kaus、Michael Burkard、Matthew Martinson、Huifen Chen、Brian Dean、Danette A. Dudley、Stephen E. Gould、Patricia Pacheco、Sheerin Shahidi-Latham、Weiru Wang、Kristina West、Jianping Yin、John Moffat、Jacob B. Schwarz

  DOI：10.1016/j.bmcl.2014.04.068

  日期：2014.6

  The discovery and optimization of a series of tetrahydropyridopyrimidine based extracellular signal-regulated kinase (Erks) inhibitors discovered via HTS and structure based drug design is reported. The compounds demonstrate potent and selective inhibition of Erk2 and knockdown of phospho-RSK levels in HepG2 cells and tumor xenografts. (C) 2014 Elsevier Ltd. All rights reserved.